Introduction
============

Exacerbations are an important feature of chronic obstructive pulmonary disease (COPD) since they result in deterioration of a patient's quality of life ([@b107-copd-3-217]), contribute to decline in lung function ([@b36-copd-3-217]), and lead to over 50% of all COPD-related costs ([@b103-copd-3-217]; [@b73-copd-3-217]). A disease state with such important consequences is in need of a tight definition, yet there is no consensus on such a definition. Several definitions have been proposed, focussing mostly on symptoms, sometimes in combination with infectious etiology ([@b67-copd-3-217]; [@b33-copd-3-217]; [@b98-copd-3-217]). The most quoted definition is the one proposed by Anthonisen ie, a disease state characterized by an increase in symptoms of dyspnea, sputum volume and sputum purulence ([@b8-copd-3-217]). Although many physicians consider an increase in inflammation as a core feature of an acute COPD exacerbation and indeed several studies provide evidence that this is the case, (see later in this review), none of the definitions in use for acute exacerbations capture the term inflammation. A first effort using inflammatory biomarkers to objectively confirm COPD exacerbations has been published recently. This study showed that plasma C-reactive protein in combination with one major symptom is useful to confirm an exacerbation of COPD ([@b58-copd-3-217]). It is important to focus on inflammation, since it gives insight into the pathological changes causing an exacerbation, thereby possibly providing directions for future therapies which modify inflammation.

Bronchodilators and corticosteroids are the most commonly used drugs to treat exacerbations of COPD. Corticosteroids elicit a very broad array of anti-inflammatory actions. The use of systemic corticosteroids as treatment in COPD exacerbations is evidence-based ([@b130-copd-3-217]). The beneficial clinical effects have been extensively investigated, but less is known of the underlying anti-inflammatory effects of corticosteroids in exacerbations of COPD. In humans, only one placebo-controlled study (published in abstract form, see [@b17-copd-3-217]) has investigated the anti-inflammatory mechanisms of steroids in COPD exacerbations, showing a suppressive effect of corticosteroids on sputum eosinophils.

It is difficult but certainly not impossible to study aspects of inflammation even during acute exacerbations of COPD. For instance, it has been shown that sputum can safely be induced also in patients with severe airflow limitation ([@b20-copd-3-217]; [@b88-copd-3-217]). Furthermore, techniques such as exhaled breath condensate can be applied but their repeatability is poor and it is uncertain which compartment (luminal, bronchial wall, alveolar, and parenchyma) the measured biomarkers reflect. More invasive assessment of inflammation in specific lung compartments by bronchial biopsy, broncho-alveolar lavage, and theoretically even transbronchial biopsy is severely restricted during acute exacerbations for obvious safety and ethical reasons. Evaluating autopsies of patients who died during COPD exacerbations would be very informative, but, to the best of our knowledge there are no reports of histopathology of lung tissue of patients deceased during COPD exacerbation.

The information on inflammation in COPD exacerbations is fragmentary so far, because mainly cross-sectional information has been obtained during exacerbations without information during the prior stable state and only occasionally information after the resolution of the exacerbation. Such information is necessary, since it will allow dissection of the predisposing factors, types of exacerbations, and patterns of resolution. The majority of information on inflammation during exacerbations in COPD is derived from studies using sputum inductions. Induced sputum is preferred to spontaneous sputum, since not all patients produce sputum spontaneously, and induced sputum contains higher percentage viable cells ([@b20-copd-3-217]).

Many factors have to be taken into account when assessing inflammation in acute exacerbations of COPD, given the mixed etiology of these COPD exacerbations. The major causes of exacerbations which have been identified are viral and bacterial infection, and air pollution ([@b113-copd-3-217]; [@b39-copd-3-217]). In approximately a third of all exacerbations a cause cannot be identified ([@b125-copd-3-217]). Certainly the different known causes of exacerbation will result in various types of inflammation ([@b83-copd-3-217]). Furthermore, concomitant use of medication such as inhaled or oral corticosteroids have to be taken into account, since they affect the type of inflammation ([@b12-copd-3-217]).

The aim of the current review is to provide a cell-by-cell overview of the inflammatory processes during COPD exacerbations. We will evaluate cell numbers, activation, and cytokine production, cellular interactions, damaging effects of inflammatory mediators to tissue, and the relation to symptoms at the onset of COPD exacerbations. We also speculate on future therapeutic options to modify inflammation during COPD exacerbations.

Inflammation
============

Neutrophils
-----------

Neutrophil numbers are slightly, but significantly increased in bronchial glands, submucosa, and in subepithelial tissue in bronchial biopsies in stable COPD, compared with healthy persons (smokers or nonsmokers), and the numbers of neutrophils positively related to severity of the airflow limitation ([@b105-copd-3-217]; [@b35-copd-3-217]; [@b102-copd-3-217]). The latter might result from bacterial colonisation, which may be present in sputum in the case of severe airflow limitation ([@b10-copd-3-217]; [@b109-copd-3-217]).

In COPD exacerbations, neutrophils are increased in both the submucosa and subepithelial tissue compared with the stable disease ([@b90-copd-3-217]; [@b43-copd-3-217]; [@b74-copd-3-217]; [@b118-copd-3-217]; [@b17-copd-3-217]; [@b83-copd-3-217]). The presence of potential pathogenic microorganisms in sputum in exacerbations is associated with higher neutrophil numbers ([@b49-copd-3-217]), as in stable disease. Exacerbations are associated with increased sputum neutrophil numbers and the change in neutrophil numbers correlate with greater decrease in forced expiratory volume in one second (FEV~1~) during exacerbations ([@b83-copd-3-217]; [@b127-copd-3-217]) ([Figure 1](#f1-copd-3-217){ref-type="fig"}). At the time of the resolution of exacerbations, a decrease in neutrophil number is associated with eradication of bacteria from sputum ([@b125-copd-3-217]). A postulated underlying mechanism for this neutrophilia is the interaction of bacteria with Toll-like receptors on antigen presenting cells and epithelial cells by bacteria, which induces the release of pro-inflammatory cytokines, as with viral infections ([@b124-copd-3-217]; [@b97-copd-3-217]). Although neutrophils show a relation with the presence of bacteria in both stable COPD and exacerbations, the increase in neutrophils is not limited to bacterial exacerbations: neutrophils have been shown to increase also during exacerbations associated with viral infections and in those without demonstrable pathogens ([@b83-copd-3-217]).

The most potent chemoattractants of neutrophils are leukotriene B4, interleukin-8 (IL-8), epithelial-derived neutrophil attractant-78, and tumor necrosis factor-α (TNF-α) ([@b104-copd-3-217]; [@b16-copd-3-217]; [@b43-copd-3-217]; [@b74-copd-3-217]; [@b83-copd-3-217]). COPD patients with frequent exacerbations have higher IL-8 levels in sputum in the stable phase compared to patients with infrequent exacerbations, illustrating the important role of neutrophil chemoattraction in the pathophysiology of COPD exacerbations ([@b119-copd-3-217]). The recruitment of neutrophils is facilitated by increased expression of adhesion molecules on the surface of circulating neutrophils, which are stress-inducible and up-regulated during COPD exacerbations ([@b6-copd-3-217]; [@b108-copd-3-217]; [@b78-copd-3-217]). Leukotrienes are also very potent chemoattractants of inflammatory cells during COPD exacerbations. Not only leukotriene B4, but also leukotriene E4 is increased during exacerbations and related to blood oxygen tension and airway obstruction in the course of exacerbations ([@b110-copd-3-217]; [@b49-copd-3-217]; [@b22-copd-3-217]).

One of the main functions of neutrophils is their antibacterial role. To kill bacteria, neutrophils degranulate, releasing myeloperoxidase, a highly reactive acidic oxidant ([@b44-copd-3-217]), which is increased during COPD exacerbations, both in sputum and serum ([@b1-copd-3-217]).

Chronic obstructive pulmonary disease exacerbations caused by bacterial infections resulting in increased sputum neutrophils, often evoke a systemic inflammatory response: inflammatory markers such as circulating neutrophil numbers, C-reactive protein, fibrinogen, and serum IL-6 are increased during exacerbations ([@b123-copd-3-217]; [@b58-copd-3-217], [@b59-copd-3-217]). Several mechanisms have been proposed for the origin of the increased systemic inflammation. These include:1) spill over of inflammatory mediators from the pulmonary compartment; 2) an inflammatory reaction to tissue hypoxia; 3) a reaction induced by the pro-inflammatory bacterial product lipopolysaccharide ([@b132-copd-3-217]).

Systemic inflammation could be important in the follow-up of exacerbations, since COPD patients with frequent exacerbations have a smaller reduction of systemic inflammatory markers in the recovery of an exacerbation, and nonrecovery of an exacerbation is related to persistently increased systemic inflammation ([@b86-copd-3-217]). Furthermore, systemic inflammation during COPD exacerbations may induce cardiovascular co-morbidity, by causing hemostasis and thrombosis. However, a relationship between increased inflammation caused by infections during exacerbations and the risk for cardiovascular heart disease has yet not been proven ([@b123-copd-3-217]; [@b101-copd-3-217]; [@b66-copd-3-217]).

In conclusion, neutrophils are predominantly increased in more severe exacerbations caused by bacterial infections, however this increase is not limited to bacteria-associated exacerbations alone.

Eosinophils
-----------

Eosinophilic inflammation is generally not associated with COPD. In a stable phase, there is little evidence for a role of eosinophils except in a specific COPD phenotype, which shows little emphysema and bronchial wall thickening on computed tomography scans and a good response to corticosteroids ([@b87-copd-3-217]; [@b42-copd-3-217]; [@b26-copd-3-217], [@b24-copd-3-217]; [@b61-copd-3-217]). This COPD phenotype has many features of asthma, and it would be of interest to compare in airway tissue histology from patients with this particular COPD phenotype and that of asthma patients. During COPD exacerbations it is recognised that an "asthma-like" inflammatory pattern in the airways may exist with increased numbers of eosinophils ([@b14-copd-3-217]). At least 5 studies have found this in mild to moderate COPD exacerbations in airway wall biopsies, and by broncho-alveolar lavage and sputum induction, although some of these studies also included patients with chronic bronchitis without airway obstruction (17; 19; 27--29) ([Figure 2](#f2-copd-3-217){ref-type="fig"}). The increase in eosinophils during exacerbations shown in [Figure 2](#f2-copd-3-217){ref-type="fig"} suggests that there is a subset of patients in which airway eosinophilia increases. The increase in eosinophils during COPD exacerbations is at least partially related to viral infections ([@b84-copd-3-217]; [@b99-copd-3-217]). Pathogens are recognized by Toll-like receptors on epithelial cells, which induce the release of several pro-inflammatory cytokines ([@b54-copd-3-217]; [@b97-copd-3-217]). The eosinophil attracting chemokines "Regulated upon Activation, Normal T-cell Expressed, and Secreted" (RANTES), eotaxin, and interleukin-5 (IL-5) have been reported to be increased during COPD exacerbations ([@b135-copd-3-217]; [@b23-copd-3-217]; [@b99-copd-3-217]; [@b43-copd-3-217]).

Although, as documented above, the eosinophil has been consistently shown to be associated with COPD exacerbations, many clinicians do not intuitively consider this a relevant cell to target in the treatment of exacerbations. It is interesting, however, to realise that the eosinophil is the most steroid sensitive cell in the airways and that much of what is achieved with corticosteroids during exacerbations may be related to effects of steroids on eosinophils ([@b33-copd-3-217]; [@b76-copd-3-217]). In stable COPD, it has been shown that higher number of eosinophils correlate with responsiveness to both oral and inhaled corticosteroids ([@b42-copd-3-217]; [@b25-copd-3-217], [@b24-copd-3-217]). Additionally, it has been shown recently that both prednisolone and the combination of inhaled budesonide plus formoterol suppress sputum eosinophilia during COPD exacerbations ([@b17-copd-3-217]).

Whether this steroid-induced decrease in eosinophils has clinical benefit has not directly been proven. However, a decrease of soluble interleukin-5 receptor alpha in the resolution phase of a virus-induced exacerbation has been related to an increase in FEV~1~, suggesting that such a relationship may exist (Rohdeet al 2004).

Not only the eosinophils themselves, but also their products such as eosinophil cationic protein are increased in sputum and in serum during COPD exacerbations ([@b40-copd-3-217]; [@b43-copd-3-217]). Eosinophil cationic protein among other effects causes tissue damage and tissue remodelling in in vitro studies ([@b134-copd-3-217]). This could explain at least part of the association between exacerbation frequency and excess decline in lung function ([@b36-copd-3-217]).

Lymphocytes
===========

Stable disease
--------------

Lymphocytes are thought to play an important role in the development and progression of COPD. Particularly CD8+ lymphocytes have been intensively investigated. CD8+ cells are increased in the airway submucosa and in peripheral blood in patients with stable COPD, and the number of CD8+ cells is positively related to the severity of airflow limitation ([@b34-copd-3-217]; [@b79-copd-3-217]; [@b100-copd-3-217]). Most CD8+ cells are supposed to represent cytotoxic memory cells, which are produced after a first airway infection, and facilitate a faster and more effective response of the immune system when the next infection occurs. Indeed, in vivo studies show that more effective airway viral clearance is associated with higher CD8+ cell numbers. CD8+ cell numbers in the airways remain high for several months after viral infections, and stabilize after 6 months ([@b57-copd-3-217]; [@b65-copd-3-217]; [@b55-copd-3-217]). The higher CD8+ numbers in stable COPD patients may be caused by the occurrence of an airway infection in the preceding few months, or alternatively there is a continuous low grade infection and the numbers of CD8+ cells reflect the need to protect the lung tissue ([@b71-copd-3-217]; [@b96-copd-3-217]; [@b131-copd-3-217]). CD4+ cells, the helper T cells which produce pro-inflammatory cytokines, have also been reported to be increased in the peripheral blood of patients with COPD, particularly the interferon gamma producing cells ([@b69-copd-3-217]).

Several recent studies have also shown that B-cells are increased in bronchiolar and bronchial walls in the stable phase of COPD ([@b56-copd-3-217]; [@b50-copd-3-217]; [@b121-copd-3-217]). B-cells play a role in the humeral immune response, producing antibodies to antigens. The pathological role of the increased B-cells in COPD is still uncertain. It has been speculated that viral airway infections may underlie the rise in B-cells ([@b46-copd-3-217]; [@b32-copd-3-217]), but an autoimmune response, perhaps in reaction to cigarette smoke components or extracellular matrix products has also been postulated ([@b68-copd-3-217]; [@b5-copd-3-217]; [@b121-copd-3-217]).

Exacerbations
-------------

During exacerbations lymphocytes in both induced sputum and tissue biopsies increase even further ([@b104-copd-3-217]; [@b43-copd-3-217]; [@b74-copd-3-217]; [@b17-copd-3-217]) ([Figure 3](#f3-copd-3-217){ref-type="fig"}). This could partly be explained by the role of lymphocytes in the clearance of viruses. Despite consistent reports of the involvement of lymphocytes in COPD exacerbations, little data has been published on the lymphocyte subpopulations which are involved. In a small study, a CD8 type 2 mediated immune reaction occurred during COPD exacerbations ([@b117-copd-3-217]). To the best of our knowledge, no information on B-cells in COPD exacerbations has been published. We have no real insight on whether the changes in lymphocytes during exacerbations are a normal appropriate, an insufficient, or even an inappropriate or excessive response. If the response is insufficient, higher levels of specific lymphocytes may be more protective. Vaccination might be an intervention to increase the levels of specific lymphocytes. To explore whether vaccinations could be an effective intervention to prevent COPD exacerbations, more insight on the role of the lymphocyte and their subpopulations is needed. A large observational trial aiming to assess the role of T-cells in COPD exacerbations, which has started recruiting, will hopefully provide more information on this topic (ClinicalTrials.gov Identifier: NCT00281229).

In summary, airway infections are a common cause of COPD exacerbations, and as lymphocytes are the regulatory cells of immune response to infections, they could very well be key-players in the increased inflammation in both stable COPD and in the onset of COPD exacerbations, but the exact mechanisms by which the influx of cells is generated, their activation state, and their resulting effects still need to be elucidated.

Macrophages
===========

Smokers with stable COPD have increased numbers of macrophages in airway tissue compared with chronic bronchitic patients without airflow limitation, or healthy controls ([@b79-copd-3-217]). The increase in macrophages is induced by smoking, since cessation of smoking in asymptomatic persons results in a decrease in sputum macrophages, and current smoking is positively related to macrophage numbers in airway submucosa and tissue ([@b128-copd-3-217], [@b129-copd-3-217]).

During exacerbations of COPD, large observational studies have not shown a significant increase in sputum or airway tissue macrophages, neither as a percentage of total cells nor as an increase in absolute cell counts ([@b104-copd-3-217]; [@b21-copd-3-217]; [@b43-copd-3-217]; [@b83-copd-3-217]). One study has even shown a significant decrease in sputum macrophages as percentage ([@b117-copd-3-217]). However, it is perhaps too early to conclude that macrophages are not involved during exacerbations. Since macrophages are responsive to cigarette smoke, a reduction in the number of cigarettes smoked during exacerbations could perhaps mask an increase in macrophages compared to the stable phase of disease. Future studies analyzing the inflammatory changes for nonsmokers separately could perhaps give a more definitive answer whether macrophages are increased during COPD exacerbation.

Air pollution
=============

Epidemiological studies have shown that air pollution, particularly with fine particulate matters, can cause of COPD exacerbations ([@b113-copd-3-217]; [@b106-copd-3-217]). Air pollution is associated with increased inflammation in the airways of elderly people, as they have higher exhaled nitric oxide levels when airway pollution increases ([@b3-copd-3-217]). There is a lack of data on cellular airway inflammation caused by airway pollution induced COPD exacerbations, probably since it is difficult to identify these exacerbations caused by air pollution singularly, and since air pollution also interacts with viruses, resulting in a mixed origin of the exacerbation ([@b48-copd-3-217]).

Oxidative stress
================

Oxidative stress is an imbalance between the amount of oxidants and the capacity of antioxidants to scavenge these radicals. This imbalance originates from either an increased load of oxidants (reactive oxygen and nitrogen species and free radicals) and/or by a decreased antioxidant capacity. The increase in oxidants may result from release from inflammatory cells, or caused by increased inhalation of oxidants in cigarette smoke or polluted air ([@b30-copd-3-217]; [@b75-copd-3-217]; [@b19-copd-3-217]). Oxidative stress induces Nuclear Factor-κB, a transcription factor involved in upregulating genes of many pro-inflammatory cytokines, resulting in increased inflammation ([@b92-copd-3-217]). Thus, inflammation induces oxidative stress and oxidative stress in turn causes increased inflammation.

Furthermore, the oxidative stress can be caused by a decreased antioxidant capacity. Theoretically, a decreased antioxidant capacity might result from poor nutritional status, however reports on the effect of food intake on the antioxidant capacity is conflicting ([@b27-copd-3-217]; [@b94-copd-3-217]). However, an increased oxidant burden may lead to depletion of antioxidants in epithelial lining fluid in exacerbations of COPD (98). Another possibility could be a dysfunction of antioxidant producing enzymes ([@b133-copd-3-217]; [@b53-copd-3-217]).

During exacerbations, the antioxidant capacity is decreased, both in blood and in the airway submucosa ([@b93-copd-3-217]; [@b37-copd-3-217]). This decrease in antioxidant capacity is probably caused by an increased requirement for the scavenging of oxidants, since hydroxygenperoxidase and 8-isoprostane, both products of reactions with oxygen radicals, are increased during COPD exacerbations in exhaled breath condensate ([@b22-copd-3-217]; [@b47-copd-3-217]; [@b82-copd-3-217]).

Thus, oxidative stress is involved in COPD exacerbations, since there is an increased load of oxidants and the antioxidant capacity is decreased. It cannot be determined whether oxidative stress is a pathogenic cause of exacerbations, or a consequence of increased inhalation of oxidants, or infection with an increased inflammation.

Anti-inflammatory therapies
===========================

Modification of inflammation during COPD exacerbations is not without potential risks, since inflammatory cells play a role in defence against pathogens. Ideally any modification should improve symptoms and inflammatory damage, without increasing the risk of consequent infections. In vivo models of COPD exacerbations would be useful to test new anti-inflammatory drugs. Unfortunately, successful in vivo models for COPD exacerbations have not yet been reported as far as we know.

The only proven successful inflammation modifying therapy for COPD exacerbations thus far is treatment with corticosteroids. Treatment of COPD exacerbations with systemic corticosteroids improves lung function and oxygenation, reduces treatment failures, and shortens the length of hospital stay ([@b116-copd-3-217]; [@b33-copd-3-217]; [@b76-copd-3-217]; [@b70-copd-3-217]). These beneficial effects are evidence based, however the magnitude of effect is modest. Lung function improves in the first 72 hours of treatment, but the improvement is not significantly different compared to placebo treatment after 2 weeks suggesting a spontaneous recovery in many patients. The reduction in length of hospitalisation with systemic steroids is 1--2 days ([@b33-copd-3-217]; [@b76-copd-3-217]; [@b70-copd-3-217]). However, these gains with steroid treatment come at a price. Treatment with systemic corticosteroids results in adverse systemic effects, such as hyperglycaemia, insomnia, and weight gain ([@b33-copd-3-217]; [@b70-copd-3-217]; [@b2-copd-3-217]). It has been calculated that one extra adverse effect occurs for every 6 patients treated with systemic corticosteroids ([@b130-copd-3-217]).

To avoid systemic adverse effect of oral steroids, treatment with inhaled steroids at an increased dose compared to the maintenance dose might be an option. Indeed, in one study treatment of COPD exacerbations with inhaled steroids improved lung function compared to placebo treatment, and caused less systemic effects than systemic steroid treatment ([@b70-copd-3-217]). Since maximal bronchodilation and steroids are the current standard treatment of COPD exacerbations, combined long-acting bronchodilators, and inhaled steroids is a logical next intervention. A single study has investigated treatment of COPD exacerbations with combined budesonide and formoterol, which resulted in a decrease in sputum eosinophils, and an improvement of symptoms and health status ([@b17-copd-3-217]). A larger study powered to document improvement in airflow limitation is under way and investigates whether this combined therapy is as effective as systemic steroids in the treatment of COPD exacerbations (ClinicalTrials.gov Identifier: NCT00259779).

The data on inflammation that observational studies of COPD exacerbations have provided, can potentially lead to development of novel inflammation modifying drugs. Some of these drugs have already been tested in the stable phase of COPD, and could be beneficial in the treatment of exacerbations.

Modification of inflammation by leukotriene antagonists has been tested in the treatment of stable COPD ([@b13-copd-3-217]; [@b28-copd-3-217]). Both treatment of stable COPD patients with montelukast, a leukotriene receptor antagonist, and with BAYx1005 a leukotriene synthesis inhibitor resulted in a reduction in neutrophil numbers in sputum. Leukotriene B4 has been shown to be involved in the chemoattraction of neutrophils during exacerbations ([@b22-copd-3-217]). Therefore, treatment to reduce leukotriene levels might also be beneficial in COPD exacerbations.

Phosphodiesterase (PDE)-4 inhibition is an anti-inflammatory mechanism that inhibits the break down of cyclic adenosine monophosphate in inflammatory cells ([@b15-copd-3-217]). This results in higher intracellular cyclic adenosine monophosphate, which inactivates pro-inflammatory transcription factors by protein kinase A. Trials in patients with stable COPD showed improvements in lung function, quality of life, and exacerbation rates with this treatment ([@b91-copd-3-217]; [@b95-copd-3-217]). A reduction of bronchial wall CD8+ cells and macrophages has been demonstrated in stable disease, but the effect was rather small ([@b45-copd-3-217]; [@b60-copd-3-217]). PDE-4 inhibitors have not been tested in the treatment of COPD exacerbations.

Tumor necrosis factor-α is a general pro-inflammatory cytokine, and its levels are increased in sputum at the onset of COPD exacerbations ([@b1-copd-3-217]). Inhibition of TNF-α could lead to a reduction in inflammation during COPD exacerbations. Systemic anti-TNF-α administration has been tested in 22 patients with mild-to moderate COPD, yet in a stable phase of disease ([@b122-copd-3-217]). This study showed no positive effects. Perhaps more severe COPD, or more specifically COPD exacerbations, would be an appropriate indication for anti-TNF-α treatment.

Inhibition of cytokines involved in the recruitment of eosinophils, such as IL-5, RANTES, and eotaxin could also be a strategy to modify inflammation during COPD exacerbations. This has not been studied in COPD so far. In vitro studies and studies in patients with asthma show beneficial effects of such specific antieosinophil therapies, and perhaps these therapies should be tested as a treatment of COPD exacerbations ([@b38-copd-3-217]; [@b52-copd-3-217]; [@b115-copd-3-217]; [@b89-copd-3-217]; [@b63-copd-3-217]; [@b31-copd-3-217]; [@b41-copd-3-217]; [@b62-copd-3-217]; [@b114-copd-3-217]).

Another pathway to reduce inflammation is inhibition of the mitogen-activated protein (MAP)-kinase pathway. MAP-kinase pathways are involved in the signal transduction from an external inflammatory stimulus to an inflammatory response, by activating intracellular transcription factors for pro-inflammatory cytokine gene expression ([@b64-copd-3-217]). In vivo studies investigating MAP-kinase inhibitors show reducing effects on neutrophil inflammation in a lipopolysaccharide inhalation model, and on eosinophilic inflammation in an allergy model ([@b120-copd-3-217]; [@b29-copd-3-217]). The first generation MAP-kinase inhibitors had significant side effects in humans. A second generation is in development with fewer side effects ([@b4-copd-3-217]) and might be introduced in the treatment of airway inflammatory diseases in the near future, including COPD exacerbations.

Macrolides are well known for their antimicrobial activity. Besides their antimicrobial activity, macrolides have anti-inflammatory effects. They reduce pro-inflammatory cytokine production, and neutrophilic and eosinophilic inflammation ([@b51-copd-3-217]). Part of these anti-inflammatory effects involve the extracellular regulated protein kinase pathway, a MAP-kinase pathway ([@b111-copd-3-217]). Macrolide treatment in stable COPD patients induced a reduction in neutrophilic inflammation without improvement in health status or exacerbation rate ([@b11-copd-3-217]; [@b85-copd-3-217]). We did not find any reports on the effects of COPD exacerbations with macrolides compared to other antibiotics in relation to their anti-inflammatory properties.

Inhibition of MAP-kinase can also be established by inhalation of low dose carbon monoxide (CO) ([@b80-copd-3-217]). CO inhalation is usually associated with toxic effects which occur during exposure to high doses or to long-term low levels. In contrast, exposure to low dose CO can be cytoprotective ([@b81-copd-3-217]), and both in vitro and in vivo studies have shown its anti-inflammatory effects on the airways ([@b29-copd-3-217]; [@b7-copd-3-217]; [@b77-copd-3-217]). Inhalation of low dose CO in an ovalbumin-induced allergic in vivo model attenuates the eosinophilic inflammation by reducing IL-5 levels, and reduces bronchial hyperresponsiveness to methacholine ([Figure 4](#f4-copd-3-217){ref-type="fig"}). Therefore, CO has been postulated to have a potential therapeutic role in pulmonary medicine ([@b112-copd-3-217]). The effects of inhaled CO have been tested in healthy volunteers, who were infused with lipopolysaccharide, but CO did not influence plasma TNF-α, IL-6, and IL-8 levels, which were increased by lipopolysaccharide ([@b72-copd-3-217]). Since the predominant effect of CO seems to be a reduction of eosinophils, asthma and COPD exacerbations could be more appropriate indications. The results of anti-inflammatory effects of inhaled CO on inflammatory airway diseases will appear in the near future ([@b18-copd-3-217]).

Conclusions
===========

During COPD exacerbations, there is increased airway wall inflammation, with pathophysiological influx of eosinophils, neutrophils, and lymphocytes. There are no reports of increased macrophages during COPD exacerbations. Although links have been suggested between the increase in eosinophils and lymphocytes and a viral etiology of the exacerbation, and between the increase in neutrophils and a bacterial etiology, these increases in both inflammatory cell types are not limited to the respective etiologies and the underlying mechanisms remain elusive. Reports on increases in lymphocytes during COPD exacerbations are consistent, and they might play a key role in the protection against recurrent infections, which evoke an inflammatory response. There is little data on the subtypes of lymphocytes involved in the onset of COPD exacerbations, which would be essential to dissect the normal from the pathophysiological immune response, which may be increased either excessively or insufficiently. Studies that document the onset of inflammatory changes in COPD exacerbations should prove useful to develop inflammation-modifying interventions.

The only successful inflammation-modifying drugs during exacerbations so far are corticosteroids, but their beneficial effects are modest and steroids do have important side effects. New data suggest that the use of inhaled steroids (in combination with long-acting bronchodilators) may be an alternative to systemic steroids in the treatment of exacerbations with less potential for systemic side effects. Whether this is as effective as systemic steroids needs to be assessed in future studies.

Several more specific cytokine or pathway inhibiting drugs are in development for stable COPD. A further step might be to test these drugs also in COPD exacerbations. However, it is also possible that new drugs that specifically target inflammatory changes pertinent to COPD exacerbations can be developed. In conclusion, further research is required to fully understand the inflammatory mechanisms in the onset and development of COPD exacerbations. This might make inflammatory pathway-specific intervention possible, resulting in a more effective treatment of COPD exacerbations with fewer side effects.

![An increase in neutrophils concurs with a drop in FEV~1~ during a COPD exacerbation. Data of 64 patients. Copyright © 2006. Reproduced with permission from from [@b83-copd-3-217]. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. *Am J Respir Crit Care Med*, 173:1114--21.\
**Abbreviations:** COPD, chronic obstructive pulmonary disease; FEV~1~, forced expiratory volume in one second.](copd-3-217f1){#f1-copd-3-217}

![Changes in sputum eosinophil numbers from stable phase of COPD to the onset of an exacerbation. Copyright © 2005. Reproduced with permission [@b43-copd-3-217]. Airway inflammation during stable and acutely exacerbated chronic obstructive pulmonary disease. *Eur Respir J*, 25:640--6.\
**Abbreviation:** COPD, chronic obstructive pulmonary disease.](copd-3-217f2){#f2-copd-3-217}

![Lymphocytes are involved in the onset of COPD exacerbations. CD8+ cells are increased at COPD exacerbations, causing a decreased CD4/CD8 ratio. Copyright © 2005. Reproduced with permission from [@b117-copd-3-217]. Changes in sputum T-lymphocyte subpopulations at the onset of severe exacerbations of chronic obstructive pulmonary disease. *Respir Med*, 99:572--9.\
**Abbreviation:** COPD, chronic obstructive pulmonary disease.](copd-3-217f3){#f3-copd-3-217}

![In an aero-allergen induced allergic inflammation mice model, inhaled carbon monoxide (CO) reduced inflammatory cell counts (×104/mL) in broncho-alveolar lavage fluid. Treated animals (CO) received 250 parts per million inhaled carbon monoxide 2 hours before the aero-allergen challenge (OVA) and continuously thereafter. Control animals were kept in room air (RA) for the duration of the experiment. Copyright © 2001. Reproduced with permission from [@b29-copd-3-217]. Carbon monoxide attenuates aeroallergen-induced inflammation in mice. *Am J Physiol Lung Cell Mol Physiol*, 281:L209--L216.\
**Notes:** \*Significantly increased (p \< 0.05) from sham-challenged animals; †Significantly different (p \< 0.05) from mice kept in room air; ††Significantly different (p \< 0.0007) from mice kept in room air.](copd-3-217f4){#f4-copd-3-217}

###### 

Studies reporting increased airway neutrophils during exacerbations compared with stable phase

  Study                Number of patients in stable phase/*exacerbation*   FEV~1~ % of predicted in stable phase/*exacerbation*   Number of sputum neutrophils in stable phase/*exacerbation*          \% sputum neutrophils in stable phase/*exacerbation*    Method
  -------------------- --------------------------------------------------- ------------------------------------------------------ -------------------------------------------------------------------- ------------------------------------------------------- ------------------
  [@b83-copd-3-217]    64/*64*                                             49.5/*39.4*                                            9.5/*26.7* × 10^6^/gram[a](#tfn1-copd-3-217){ref-type="table-fn"}    nr                                                      Sputum induction
  [@b117-copd-3-217]   12/*12*                                             40/nr                                                  nr                                                                   83.5/*98.0*[a](#tfn1-copd-3-217){ref-type="table-fn"}   Sputum induction
  [@b17-copd-3-217]    39/*39*                                             61/*51*                                                3.2/*7.1* × 10^6^/mL[a](#tfn1-copd-3-217){ref-type="table-fn"}       72.5/*72.0*                                             Sputum induction
  [@b74-copd-3-217]    19/*12*                                             nr/*37.6*                                              1.48/*2.19* × 10^6^/gram[a](#tfn1-copd-3-217){ref-type="table-fn"}   80.0/*87.5*                                             Sputum induction
  [@b43-copd-3-217]    30/*30*                                             52.9/*40.6*                                            4.4/*24.4* × 10^6^/gram[a](#tfn1-copd-3-217){ref-type="table-fn"}    83.4/*81.7*                                             Sputum induction
  [@b9-copd-3-217]     8/*5*                                               71/*64*                                                10/*83* × 10^3^/mL[a](#tfn1-copd-3-217){ref-type="table-fn"}         nr/nr                                                   BAL

**Notes:** p \< 0.05; nr, data not reported.

###### 

Studies reporting increased airway eosinophils during exacerbations compared with stable phase

  Study               Number of patients in stable phase/*exacerbation*   FEV~1~ % of predicted in stable phase/*exacerbation*   Number of sputum eosinophils in stable phase/*exacerbation*          \% sputum eosinophils of in stable phase/*exacerbation*   Method
  ------------------- --------------------------------------------------- ------------------------------------------------------ -------------------------------------------------------------------- --------------------------------------------------------- ------------------
  [@b43-copd-3-217]   30/*30*                                             52.9/*40.6*                                            0.1/*1.3* × 10^6^/gram[a](#tfn2-copd-3-217){ref-type="table-fn"}     1.7/*6.7*[a](#tfn2-copd-3-217){ref-type="table-fn"}       Sputum induction
  [@b17-copd-3-217]   39/*39*                                             61/*51*                                                0.1/*0.4* × 10^6^/mL[a](#tfn2-copd-3-217){ref-type="table-fn"}       2.7/*2.8*                                                 Sputum induction
  [@b74-copd-3-217]   19/*12*                                             nr/*37.6*                                              0.01/*0.07* × 10^6^/gram[a](#tfn2-copd-3-217){ref-type="table-fn"}   0.75/*1.0*                                                Sputum induction
  [@b9-copd-3-217]    8/5                                                 71/*64*                                                1.9/*6.7* × 10^3^/mL[a](#tfn2-copd-3-217){ref-type="table-fn"}       nr/nr[a](#tfn2-copd-3-217){ref-type="table-fn"}           BAL
  [@b83-copd-3-217]   15/*15* subgroup viral exacerbations                nr/nr                                                  0.9/*3.5* × 10^6^/gram[a](#tfn2-copd-3-217){ref-type="table-fn"}     nr/nr                                                     Sputum induction

**Notes:** p \< 0.05; nr, data not reported.

###### 

Studies reporting increased airway lymphocytes during exacerbations compared with stable phase

  Study               Number of patients in stable phase/*exacerbation*   FEV~1~ % of predicted in stable phase/*exacerbation*   Number of sputum lymphocytes in stable phase/*exacerbation*          \% sputum lymphocytes in stable phase/*exacerbation*   Method
  ------------------- --------------------------------------------------- ------------------------------------------------------ -------------------------------------------------------------------- ------------------------------------------------------ ------------------
  [@b43-copd-3-217]   30/*30*                                             52.9/*40.6*                                            0.2/*0.7* × 10^6^/gram[a](#tfn3-copd-3-217){ref-type="table-fn"}     4.0/*4.9*                                              Sputum induction
  [@b17-copd-3-217]   39/*39*                                             61/*51*                                                0/*0.1* × 10^6^/mL[a](#tfn3-copd-3-217){ref-type="table-fn"}         0.3/*0.7*[a](#tfn3-copd-3-217){ref-type="table-fn"}    Sputum induction
  [@b74-copd-3-217]   19/*12*                                             nr/*37.6*                                              0.03/*0.31* × 10^6^/gram[a](#tfn3-copd-3-217){ref-type="table-fn"}   2.5/*4.5*                                              Sputum induction
  [@b83-copd-3-217]   64/*64*                                             49.5/*39.4*                                            0.04/*0.11* × 10^6^/gram[b](#tfn4-copd-3-217){ref-type="table-fn"}   nr                                                     Sputum induction

**Notes:** p \< 0.05;

p = 0.06; nr, data not reported.
